RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2011; 105(04): 574-578
DOI: 10.1160/TH10-12-0808
DOI: 10.1160/TH10-12-0808
Clinical Focus
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Weitere Informationen
Publikationsverlauf
Received:
20. Dezember 2010
Accepted after major revision:
20. Januar 2010
Publikationsdatum:
28. November 2017 (online)
-
References
- 1 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
- 2 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
- 3 Ezekowitz MD, Wallentin L, Connolly SJ. et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010; 122: 2246-2253.
- 4 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
- 5 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
- 6 Diener HC, Connolly SJ, Ezekowitz MD. et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-1163.
- 7 Eikelboom JW, O’Donnell M, Yusuf S. et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159: 348-353.
- 8 AVERROES: Apixaban yields significant reductions in stroke, no increased bleeding. Available at www.theheart.org Accessed on August 31, 2010.
- 9 Off orbit? ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds. Available at www.theheart.org Accessed on November 15, 2010.
- 10 Roskell NS, Lip GY, Noack H. et al. Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106-1115.
- 11 Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. Thromb Haemost 2010; 104: 657-663.
- 12 Ruiz-Nodar JM, Marin F, Manzano-Fernandez S. et al. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation undergoing percutaneous coronary revascularisation. Chest. 2010 preprint online.
- 13 Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?. Am J Med 2010; 123: 785-789.
- 14 Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-585.
- 15 Jiang J, Hu Y, Zhang J. et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects. Thromb Haemost 2010; 103: 234-241.
- 16 Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-347.
- 17 Ezekowitz MD, Connolly S, Parekh A. et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-10 810.e1–2.
- 18 Koti MJ, Parekh A, Connolly SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation – An analysis of patients undergoing cardioversion. J Am Coll Cardiol 2010; 55: 1078-1124 (Abstract).
- 19 Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005; 46: 1986-1995.
- 20 FDA approves dabigatran for stroke prevention, embolism, in AF patients. Available at www.theheart.org Accessed on October 20, 2010.
- 21 Eisert WG, Hauel N, Stangier J. et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30: 1885-1889.
- 22 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
- 23 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
- 24 Furie KL, Kasner SE, Adams RJ. et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. A Guideline for Health-care Professionals From the American Heart Association/American Stroke Association. Stroke. 2010 prepublished online.